Included in the formulation
АТХ:S.01.G.X.09 Olopatadine
Pharmacodynamics:The drug selectively blocks histamine H1-receptors, and also inhibits the release of inflammatory mediators from mast cells. Has a pronounced anti-allergic effect.
It has no effect on α-adrenergic, dopamine, muscarinic types 1 and 2, as well as serotonin receptors.
Pharmacokinetics:Local absorption is low, Cmax Olopatadine in blood plasma is achieved within 2 hours after topical application, the half-life is 3 hours, excreted by the kidneys, while 60-70% is excreted unchanged.
Indications:Allergic conjunctivitis.
VII.H10-H13.H10.1 Acute atopic conjunctivitis
Contraindications:Hypersensitivity.
Carefully:Children under 3 years of age, pregnancy and lactation.
Pregnancy and lactation:Category FDA - C. Detailed studies have not been conducted. The use of the drug during pregnancy and during lactation is possible if the expected therapeutic effect exceeds the potential risk to the fetus and the baby.
Dosing and Administration:Locally, on the 1st drop 2 times a day in the conjunctival sac.
Side effects:Burning and pain in the eyes, blurred vision, headache, weakness, nausea, dizziness, change in taste, rhinitis, nausea, pharyngitis, foreign body sensation in the eye, iritis, keratitis, lacrimation, conjunctival hyperemia.
Overdose:It is unlikely, the treatment is to rinse the eyes.
Interaction:It can be used in combination with other ophthalmic preparations, but between their use it is necessary to sustain a pause of 5 minutes.
Special instructions:Sufficient experience in children under the age of 3 years is not available. Can be used in children aged 3 years and older in the same doses as in adults.
Olopatadine contains a preservative benzalkonium chloride, which can be absorbed by contact lenses. Before instillation of a preparation of a lens it is necessary to remove and establish back not earlier than in 20 minutes after instillation of a preparation.
Do not touch the tip of the pipette with any surface to avoid contamination of the solution.
Impact on the ability to drive vehicles and manage mechanisms
If the patient's vision is temporarily reduced after applying olopatadine,then before its restoration it is not recommended to drive and engage in other activities that require a high concentration of attention and speed of psychomotor reactions.